{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T20:24:04Z","timestamp":1779135844268,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jtocrr.2022.100355","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T17:03:13Z","timestamp":1654275793000},"page":"100355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1673-2260","authenticated-orcid":false,"given":"Hayato","family":"Kawachi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohiro","family":"Tamiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihide","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Yokoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Oya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihoko","family":"Imaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fukuko","family":"Okabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Kanazu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Uematsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisaku","family":"Miyauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asuka","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"71","key":"10.1016\/j.jtocrr.2022.100355_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics","volume":"2021","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtocrr.2022.100355_bib2","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jtocrr.2022.100355_bib3","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2022.100355_bib4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2022.100355_bib5","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2022.100355_bib6","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"KEYNOTE-024 investigators, pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2022.100355_bib7","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"KEYNOTE-042 Investigators, Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2022.100355_bib8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2022.100355_bib9","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2022.100355_bib10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10637-019-00882-5","article-title":"Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study","volume":"38","author":"Kawachi","year":"2020","journal-title":"Investig New Drugs"},{"key":"10.1016\/j.jtocrr.2022.100355_bib11","first-page":"47","article-title":"Prognostic value of pleural effusion in patients with non-small cell lung cancer","volume":"3","author":"Sugiura","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2022.100355_bib12","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2022.100355_bib13","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2022.100355_bib14","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2022.100355_bib15","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2022.100355_bib16","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2022.100355_bib17","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.annonc.2021.06.004","article-title":"Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer","volume":"32","author":"Sugawara","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2022.100355_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/cdd.2013.67","article-title":"Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer","volume":"21","author":"Bracci","year":"2014","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.jtocrr.2022.100355_bib19","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1007\/s12032-013-0676-7","article-title":"Phase 2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion","volume":"30","author":"Tamiya","year":"2013","journal-title":"Med Oncol"},{"key":"10.1016\/j.jtocrr.2022.100355_bib20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.lungcan.2016.07.003","article-title":"A\u00a0phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A","volume":"99","author":"Usui","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2022.100355_bib21","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1111\/1759-7714.13472","article-title":"Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: a phase II study North East Japan Study group trial NEJ013B","volume":"11","author":"Noro","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.jtocrr.2022.100355_bib22","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"Khan","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtocrr.2022.100355_bib23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fimmu.2012.00021","article-title":"Hypoxia promotes tumor growth in linking angiogenesis to immune escape","volume":"3","author":"Chouaib","year":"2012","journal-title":"Front Immunol"},{"issue":"Pt 2","key":"10.1016\/j.jtocrr.2022.100355_bib24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.semcancer.2017.12.002","article-title":"Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics","volume":"52","author":"Hegde","year":"2018","journal-title":"Semin Cancer Biol."},{"key":"10.1016\/j.jtocrr.2022.100355_bib25","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline, 1.1 version","volume":"45","author":"Eisenhauer","year":"1990","journal-title":"Eur J Cancer (Oxford, England)"},{"key":"10.1016\/j.jtocrr.2022.100355_bib26","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermo Sifiliogr"},{"key":"10.1016\/j.jtocrr.2022.100355_bib27","doi-asserted-by":"crossref","first-page":"e004025","DOI":"10.1136\/jitc-2021-004025","article-title":"Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)","volume":"10","author":"Seto","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtocrr.2022.100355_bib28","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.cllc.2020.03.010","article-title":"Treatment rationale and design for APPLE (WJOG11218L): a multicenter, open-label, randomized phase 3 study of atezolizumab and platinum\/pemetrexed with or without bevacizumab for patients with advanced nonsquamous non-small-cell lung cancer","volume":"21","author":"Shiraishi","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtocrr.2022.100355_bib29","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/00063198-200207000-00009","article-title":"Vascular endothelial growth factor: the key mediator in pleural effusion formation","volume":"8","author":"Grove","year":"2002","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jtocrr.2022.100355_bib30","doi-asserted-by":"crossref","first-page":"672747","DOI":"10.3389\/fonc.2021.672747","article-title":"Malignant pleural effusions\u2014a window into local anti-tumor T cell immunity?","volume":"11","author":"Principe","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtocrr.2022.100355_bib31","doi-asserted-by":"crossref","first-page":"9527","DOI":"10.2147\/OTT.S224013","article-title":"Blocking TGF-\u03b2 signaling to enhance the efficacy of immune checkpoint inhibitor","volume":"12","author":"Bai","year":"2019","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.jtocrr.2022.100355_bib32","doi-asserted-by":"crossref","first-page":"6218","DOI":"10.1038\/s41467-021-26407-4","article-title":"Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy","volume":"12","author":"Bent","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtocrr.2022.100355_bib33","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41591-020-0860-1","article-title":"High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade","volume":"26","author":"Yuen","year":"2020","journal-title":"Nat Med"}],"updated-by":[{"DOI":"10.1016\/j.jtocrr.2023.100473","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000}}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364322000790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364322000790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T13:51:22Z","timestamp":1658670682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364322000790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2666364322000790"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100355","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.jtocrr.2023.100473","asserted-by":"object"}]},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100355","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100355"}}